Commitment to Patients

Press Releases

2013

June 2, 2013

Novartis pivotal Phase III trial shows Afinitor� significantly delays tumor growth in women with HER2 positive advanced breast cancer

May 29, 2013

Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA

Jan 23, 2013

Novartis drug Exjade� first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia

2012

December 14, 2012

Novartis drug Signifor� gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder

November 07, 2012

Novartis drug Signifor� recommended by FDA advisory committee for approval to treat patients with Cushing's disease

Jul 20, 2012

Novartis gains FDA approval for Afinitor� in advanced breast cancer marking a significant milestone for women battling this disease

2011

May 5, 2011

Novartis gains FDA approval for Afinitor® as first new treatment in nearly three decades for patients with advanced pancreatic NET

2010

October 29, 2010

Novartis drug Afinitor® approved by FDA as first medication for children and adults with a benign brain tumor associated with tuberous sclerosis

June 17, 2010

FDA approves Tasigna® for newly diagnosed chronic myeloid leukemia patients, data demonstrate major advance over Gleevec®

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis' website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

Press Releases

OPM Newsletter

PATIENT ASSISTANCE NOW ONCOLOGY

RESEARCH AND DEVELOPMENT